Obsidian Therapeutics files S-1 for resale of 29.16 million shares post-merger with Galera
The clinical-stage TIL cell therapy company, formed through mergers completed August 3, 2026, registers shares for selling stockholders while reporting $34.4 million in cash as of June 30, 2026.
SEC filing